Canon Medical Systems acquires Swiss MRI research and development company Skope Magnetic Resonance Technologies AG

Published on: November 26, 2019

Otawara Japan, November 26, 2019 - Canon Medical Systems Corporation (Headquarters:Otawara, Tochigi Prefecture, Japan; President and CEO: Toshio Takiguchi) has concluded a contract to acquire all shares of Skope Magnetic Resonance Technologies AG (Headquarters: Zurich, Switzerland; CEO: Christoph Barmet). With a unique research and development team, Skope is a company devoted to providing MRI users with unprecedented imaging quality and performance. The acquisition of Skope was completed according to the required approval procedures.

Skope’s expertise in MRI sensorics, signal-processing and image reconstruction covers the entire chain from signal acquisition to image generation. As a result, reproducible image quality, great image detail and time-saving MRI scanning are achieved. Skope is equipping leading MRI research sites with its high-precision magnetic field monitoring systems and, sophisticated image reconstruction software to facilitate next-generation MR imaging and diagnostics.

Canon Medical Systems succeeded in developing and introducing the first Japanese MRI in1983, and has been devoting itself to research and development of innovative MRI technologies such as Pianissimo, Canon Medical’s unique acoustic noise reduction technology, providing extraordinary patient comfort.

Canon Medical Systems is welcoming the Skope team and will leverage its talent to promote advanced research and development of MRI systems, committing to innovative MRI solutions for uncompromised patient care.

Around the web

Cardiovascular Business

Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business

‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business

FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer.